Rotigotine Transdermal Patch Does Not Make Parkinson Disease Patients Sleepy During Daytime.

Abstract:

OBJECTIVES:To assess quantitatively the influence of rotigotine transdermal patch on daytime sleepiness, the most common adverse event by non-ergot dopamine agonists (DAs), in Parkinson disease (PD) patients. METHODS:An open-label study enrolled PD patients with unsatisfactory control of motor symptoms. Treatment with rotigotine transdermal patch was titrated to optimal dose (4-8 mg/24 hours) over 2 to 4 weeks. Primary outcome was Epworth Sleepiness Scale (ESS) for daytime sleepiness. Secondary outcomes included Hoehn&Yahr stage, time spent with dyskinesia, Clinical Global Impression of Improvement (CGI-I) of motor symptoms, adverse events, and compliance. RESULTS:The subjects were 31 PD patients (age 72 ± 8, Hoehn &Yahr stage 2.7 ± 0.9, mean ± SD). The ESS did not increase after rotigotine treatment (7.2 ± 4.9 before treatment, 6.2 ± 4.0 with 4 mg/24 hour, and 8.1 ± 6.4 with 8 mg/24 hour). The CGI-I score improved after treatment; responder rate reached 88.9% with 8 mg/24 hours. No patients showed worsening in other secondary outcomes. In 13 patients treated with equivalent doses of rotigotine switched from other DAs (pramipexole, ropinirole, and cabergoline), ESS did not increase after treatment (10.0 ± 4.6 before and 8.6 ± 4.5 after treatment) and decreased without worsening of CGI-I in 54% patients. Other secondary outcomes did not worsen after treatment. CONCLUSIONS:Twenty four-hour transdermal delivery of rotigotine at doses up to 8 mg/24 hours does not worsen the daytime sleepiness in PD patients and often improves it when switched from other non-ergot DAs. This is achieved together with satisfactory improvement in motor symptoms, demonstrating that this new modality of non-ergot DA is well tolerated and beneficial in PD patients.

journal_name

Clin Neuropharmacol

authors

Ohta K,Osada T

doi

10.1097/WNF.0000000000000110

subject

Has Abstract

pub_date

2015-11-01 00:00:00

pages

231-5

issue

6

eissn

0362-5664

issn

1537-162X

journal_volume

38

pub_type

杂志文章
  • Central action of cinnarizine and flunarizine: a saccadic eye movement study.

    abstract::The mechanism of action of flunarizine (FZ) and cinnarizine (CZ) on the CNS is not fully understood. Computer analysis of saccadic eye movements (SEM) provides a sensitive and objective method for evaluating drug effect on the function of specific brain structures. This study aimed to assess the effect of a single ora...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-199410000-00003

    authors: Casucci G,Di Costanzo A,Riva R,Albani F,Bonavita V,Tedeschi G

    更新日期:1994-10-01 00:00:00

  • Effects of terguride in patients with Huntington's disease.

    abstract::trans-Dihydrolisuride, a partial dopamine receptor agonist, was tested for its effects on chorea in a double-blind, crossover clinical study in 10 patients with Huntington's disease. In eight patients, a neurophysiological evaluation was also performed. No reduction in choreic movements or improvement in voluntary mov...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-198910000-00008

    authors: Stocchi F,Carta A,Berardelli A,Antonini A,Argenta M,Formica A,Agnoli A

    更新日期:1989-10-01 00:00:00

  • Paroxysmal dystonia responsive to anticholinergic drugs.

    abstract::A case of a mentally retarded patient with sporadic paroxysmal dystonia, unresponsive to anticonvulsant therapy, is described. He had a long-standing history of neuroleptic drug intake. Trihexyphenidyl in a total daily dosage of 20 mg totally suppressed the crises. ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198708000-00007

    authors: Micheli F,Fernandez Pardal M,de Arbelaiz R,Lehkuniec E,Giannaula R

    更新日期:1987-08-01 00:00:00

  • Pergolide: multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease.

    abstract::The primary objective of this study was to describe the pharmacokinetics of oral pergolide in patients with mild to moderate Parkinson disease using a new high-performance liquid chromatography-tandem mass spectrometry assay. A secondary objective was to investigate the relationship between plasma concentrations and e...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.wnf.0000168581.97083.9c

    authors: Thalamas C,Rajman I,Kulisevsky J,Lledó A,Mackie AE,Blin O,Gillespie TA,Seger M,Rascol O

    更新日期:2005-05-01 00:00:00

  • Midazolam in the treatment of refractory neonatal seizures.

    abstract::Midazolam, a potent short-acting benzodiazepine, is a safe and highly effective agent for the control of status epilepticus. Its efficacy in the control of neonatal seizures, however, has not been determined. Six neonates (aged 1-9 days; gestation, 30-41 weeks) developed seizures from a variety of causes. In each case...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-199619020-00005

    authors: Sheth RD,Buckley DJ,Gutierrez AR,Gingold M,Bodensteiner JB,Penney S

    更新日期:1996-04-01 00:00:00

  • Low-dose clozapine for the treatment of Parkinson's disease in a patient with schizophrenia.

    abstract::Clozapine is known to be beneficial for the treatment of dopamine agonist-induced psychotic states in patients with Parkinson's disease (PD). Many reports have suggested that it may also be efficacious for the treatment of parkinsonian tremor. We describe a patient with schizophrenia in whom early-onset PD appeared af...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-200103000-00011

    authors: Orr G,Munitz H,Hermesh H

    更新日期:2001-03-01 00:00:00

  • Lack of relation between genetic polymorphism of cytochrome P-450IID6 and sporadic idiopathic Parkinson's disease.

    abstract::We investigated genetic polymorphism of the cytochrome P-450 CYP2D6 gene from white patients with idiopathic Parkinson's disease (IPD). The mutations of the CYP2D6 gene associated with the poor metabolizer (PM) phenotype of the debrisoquine/sparteine polymorphism were analyzed in DNA of 130 IPD patients by a polymeras...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199619030-00003

    authors: Bordet R,Broly F,Destée A,Libersa C,Lafitte JJ

    更新日期:1996-06-01 00:00:00

  • EEG changes induced by oxiracetam on diazepam-medicated volunteers.

    abstract::The present study was carried out in order to verify whether, in benzodiazepine-medicated healthy volunteers, oxiracetam retained the properties already observed after administration in normal volunteers. In a cross-over study, 12 volunteers, medicated the night before with 5 mg diazepam, were i.v. treated with 1 g ox...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Giaquinto S,Nolfe G,Vitali S

    更新日期:1986-01-01 00:00:00

  • An NMDA intervention strategy in schizophrenia with "low-dose" milacemide.

    abstract::Drugs (e.g., PCP) which interfere with glutamatergic transmission at the N-methyl D-aspartate (NMDA) subclass of glutamate receptors precipitate both positive and negative symptoms of psychosis in humans. Based on a proposed "glutamatergic deficiency" in schizophrenia, pharmacologic facilitation of NMDA-mediated neura...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199106000-00012

    authors: Rosse RB,Schwartz BL,Davis RE,Deutsch SI

    更新日期:1991-06-01 00:00:00

  • A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia.

    abstract::Acute psychotic episodes represent critical situations during the course of schizophrenia. Olanzapine (OLZ), a second-generation antipsychotic, is efficacious in acute settings at dosages of 5 to 20 mg/d, and it can be considered a first-line treatment for patients with an acute episode of schizophrenia. The aim of th...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/01.WNF.0000220819.71231.96

    authors: Mauri MC,Colasanti A,Rossattini M,Moliterno D,Baldi ML,Papa P

    更新日期:2006-05-01 00:00:00

  • The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders.

    abstract::The freely diffusible gaseous compound nitric oxide (NO) has recently been discovered to be an important cellular messenger in many organ systems throughout the body. The importance of NO as an intermediary in cell communication in the brain is highlighted by the fact that the excitatory amino acid glutamate, the most...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Karatinos J,Rosse RB,Deutsch SI

    更新日期:1995-12-01 00:00:00

  • Donepezil, rivastigmine, and vitamin E in Alzheimer disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months.

    abstract::The latency of P300 "cognitive" event-related potentials changes if cholinergic activities of the central nervous system are pharmacologically manipulated. We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00002826-200101000-00007

    authors: Thomas A,Iacono D,Bonanni L,D'Andreamatteo G,Onofrj M

    更新日期:2001-01-01 00:00:00

  • Effect of midazolam on memory during fiberoptic gastroscopy under conscious sedation.

    abstract:OBJECTIVE:As the fiberoptic gastroscopy using midazolam is being in widespread use, the exact nature of midazolam on memory should be clarified. We intended to examine whether midazolam causes selective anterograde amnesia and what impact it has on other aspects of memory and general cognitive function. METHODS:We rec...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0000000000000067

    authors: Hong YJ,Jang EH,Hwang J,Roh JH,Kwon M,Lee D,Lee JH

    更新日期:2015-03-01 00:00:00

  • Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neurons.

    abstract::Oxidant stress resulting from excess dopamine (DA) may contribute to the development and progression of Parkinson's disease (PD). Free radicals resulting from the enzymatic metabolism of DA are most often discussed in this regard. However, levodopa (L-DOPA) and DA can also undergo autooxidation, producing free radical...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199619040-00010

    authors: Ling ZD,Pieri SC,Carvey PM

    更新日期:1996-08-01 00:00:00

  • Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.

    abstract::Fifty-six chronic schizophrenic patients were randomized into haloperidol decanoate (HD) or placebo groups for 48 weeks of double-blind treatment. The double-blind trial was preceded by a 15-week single-blind run-in period, during which all patients were treated with 60 mg of HD (approximately corresponding to 3.6 mg ...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:

    authors: Eklund K,Forsman A

    更新日期:1991-01-01 00:00:00

  • The effects of flumazenil in neuropsychiatric disorders.

    abstract::Flumazenil is a benzodiazepine receptor antagonist. It is currently used mainly in the anaesthetic and emergency rooms to reverse the effect of exogenous benzodiazepines. Its use in a variety of experimental animal models and in human neuropsychiatric disorders continues to generate a wealth of information on the poss...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199506000-00002

    authors: Malizia AL,Nutt DJ

    更新日期:1995-06-01 00:00:00

  • Effect of cholinergic and anticholinergic drugs on short-term memory in Alzheimer's dementia: a neuropsychological and computerized electroencephalographic study.

    abstract::A correlation was found among the degree of memory loss, intellectual impairment, the quantity of senile plaques, and a decrease in choline acetyltransferase and acetylcholinesterase activity in patients affected by senile dementia of the Alzheimer type. In this study, patients were subjected to a series of computeriz...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-198312000-00005

    authors: Agnoli A,Martucci N,Manna V,Conti L,Fioravanti M

    更新日期:1983-01-01 00:00:00

  • The syndrome of irreversible lithium-effectuated neurotoxicity.

    abstract:OBJECTIVES:Persistent sequelae of lithium intoxication gained clinical attention in the 1980s and were named Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT). The authors review the published cases of SILENT reported in the literature and discuss various clinical manifestations. METHODS:The authors'...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/01.wnf.0000150871.52253.b7

    authors: Adityanjee,Munshi KR,Thampy A

    更新日期:2005-01-01 00:00:00

  • Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease.

    abstract::Male albino rats received a stereotaxic injection of 6-hydroxydopamine (6-OHDA) into the right substantia nigra. Animals demonstrating contralateral rotations 2 weeks postoperatively with apomorphine (0.5 mg/kg i.p.) were treated with L-Dopa (55 mg/kg i.p.), bromocriptine (2 mg/kg i.p.), or polyethylene glycol (vehicl...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:

    authors: Schneider MB,Murrin LC,Pfeiffer RF,Deupree JD

    更新日期:1984-01-01 00:00:00

  • Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial.

    abstract:OBJECTIVE:The purpose of this study is to investigate the safety and efficacy of aripiprazole in first-episode drug-naive patients with schizophrenia. METHODS:A total of 45 patients were enrolled in an open-label 12-week study. Dosing was determined by clinical judgment. The main efficacy measure was the Brief Psychia...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31817c6b06

    authors: Takahashi H,Oshimo T,Ishigooka J

    更新日期:2009-05-01 00:00:00

  • Platelet supersensitivity to thrombin stimulation in depression: a possible mechanism for the association with cardiovascular mortality.

    abstract::The mortality risk associated with cardiovascular disease is significantly increased in patients with major depression and panic disorder. The mechanism of this phenomenon is unclear. Thrombin is responsible for platelet aggregation and shape change, and it plays a significant role in the development of thromboembolic...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-200007000-00002

    authors: Berk M,Plein H

    更新日期:2000-07-01 00:00:00

  • A Pilot Study of Randomized, Head-to-Head of Metformin Versus Topiramate in Obese People With Schizophrenia.

    abstract:OBJECTIVES:A number of research studies support the weight loss effects of metformin and topiramate for obese people with schizophrenia. However, only a few studies have addressed the sustainability of the body weight reduction after discontinuation of these drugs. Moreover, head-to-head studies are still lacking. The ...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/WNF.0000000000000188

    authors: Peng PJ,Ho PS,Tsai CK,Huang SY,Liang CS

    更新日期:2016-11-01 00:00:00

  • Biophysical membrane interactions of steroid hormones: a potential complementary mechanism of steroid action.

    abstract::There is strong evidence to support the hypothesis that the rapid effects of steroids on neurons are membrane-mediated. Rapid steroid effects have been demonstrated in the absence of intracellular receptors, in the presence of RNA or protein synthesis inhibitors, and in response to steroids coupled to large proteins t...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Golden GA,Mason PE,Rubin RT,Mason RP

    更新日期:1998-05-01 00:00:00

  • Effective treatment with clozapine and valproate for refractory schizophrenia-like psychosis after cerebellar hemorrhage.

    abstract:BACKGROUND:The cerebellum has traditionally been regarded as an organ of motor coordination. However, the importance of the cerebellum in psychiatric disorders, behavior, and cognition is increasingly being recognized. There is no consensus concerning treatment of schizophrenia-like psychosis after cerebellar pathology...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31821f4d91

    authors: Almeida J,Serrão EM,Almeida AT,Afonso JG

    更新日期:2011-05-01 00:00:00

  • Spiking fevers with clozapine treatment.

    abstract::Clozapine often causes low-grade fever and less frequently spiking fever. We describe three cases of spiking fever that occurred in the first 3 weeks of clozapine therapy. A new set of side effects of clozapine is identified, which includes spiking fever, respiratory and gastrointestinal symptoms, and neutrophilia. Po...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-199704000-00009

    authors: Trémeau F,Clark SC,Printz D,Kegeles LS,Malaspina D

    更新日期:1997-04-01 00:00:00

  • Falls and Parkinson's disease.

    abstract::One hundred patients with Parkinson's disease (PD) and five patients with progressive supranuclear palsy were questioned about the frequency, circumstances, and consequences of falling. Parkinsonian symptoms were scored using the unified rating scale. Thirty-eight percent of parkinsonian patients fell, and 13% fell mo...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198904000-00003

    authors: Koller WC,Glatt S,Vetere-Overfield B,Hassanein R

    更新日期:1989-04-01 00:00:00

  • Biperiden withdrawal in schizophrenic inpatients receiving long-term antipsychotic medication.

    abstract::In a double-blind, 4 week study, 42 chronic schizophrenic inpatients receiving antipsychotic and antiparkinsonian (AP) drugs for greater than 3 months were either switched to placebo or maintained on biperiden. In the majority of the patients no clinically apparent discomfort was observed, and only two of 21 placebo p...

    journal_title:Clinical neuropharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00002826-198708000-00008

    authors: Wada Y,Koshino Y,Yamaguchi N

    更新日期:1987-08-01 00:00:00

  • The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome.

    abstract:INTRODUCTION:The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with Parkinson disease, and ICDs have now been reported in individuals wit...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/WNF.0b013e31820d6699

    authors: Dang D,Cunnington D,Swieca J

    更新日期:2011-03-01 00:00:00

  • Cyclosporine A neurotoxicity among bone marrow transplant recipients.

    abstract::Cyclosporine A (CsA) neurotoxicity is an iatrogenic disease with significant morbidity and occasional mortality. We retrospectively reviewed the cases of CsA neurotoxicity among bone marrow transplant recipients at our institution, and summarized the current literature on the subject. The neurologic presentation is va...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00002826-199903000-00001

    authors: Shah AK

    更新日期:1999-03-01 00:00:00

  • Mesulergine (CU 32-085) in the treatment of Parkinson's disease.

    abstract::The long-term effects of mesulergine, a new drug with dopamine agonistic properties, were studied in 28 patients with Parkinson's disease. In 18 patients with late side effects of levodopa, the addition of mesulergine (10.9 mg/day) induced significant decreases in the global (-48%), rigidity (-62%), and akinesia (-37%...

    journal_title:Clinical neuropharmacology

    pub_type: 杂志文章

    doi:10.1097/00002826-198604000-00005

    authors: Rascol A,Montastruc JL,Rascol O,Senard JM

    更新日期:1986-01-01 00:00:00